转化生长因子-β1和可溶性共抑制性免疫检查点作为基底细胞癌患者免疫抑制的假定驱动因素
Mahlatse C M Kgokolo1, Nonkululeko Z Malinga1, Helen C Steel2
1Department of Dermatology, School of Medicine, Faculty of Health Sciences, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa.
Translational oncology
|February 3, 2024
概括
基本细胞癌 (BCC) 患者表现出免疫抑制可溶性免疫检查点 (SICP) 的水平升高. 转化生长因子-β1 (TGF-β1) 与这些sICPs密切相关,这表明它在与BCC相关的免疫抑制中的作用.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 在瘤学瘤学.
背景情况:
- 基础细胞癌 (BCC) 是一种常见的皮肤癌.
- 免疫检查点在调节免疫反应方面发挥着至关重要的作用.
- 了解BCC的免疫微环境对于治疗策略至关重要.
研究的目的:
- 为了比较BCC患者的全身可溶性免疫检查点 (SICP) 和免疫抑制细胞的幽默调节器与健康对照.
- 调查sICPs与BCC中的特定免疫抑制因子之间的关联.
- 探索转化生长因子-β1 (TGF-β1) 在与BCC相关的免疫抑制中的潜在作用.
主要方法:
- 在40名BCC患者和20名健康对照群中分析了17个可溶性免疫检查点 (SICP) 和7个幽默调节器的血水平.
- 利用相关热图来识别不同分子之间的关联.
- 包括酶 (阿基因酶1,FAP),化学因子 (RANTES),细胞因子 (IL-10,TGF-β1),以及M2巨细胞标记物 (sCD163,sCD206).
主要成果:
- 在BCC患者中,六种协同抑制的sICP (sCTLA-4,sLAG-3,sPD-1,sPD-L1,sTIM-3,sPD-L2) 和两个协同刺激的sICP (sCD27,sGITR) 的水平明显升高.
- 在BCC患者中观察到sBTLA水平降低和sHVEM水平升高.
- 在TGF-β1和多个协同刺激和协同抑制的sICPs以及sTLR2之间发现了强烈的正相关性.
结论:
- BCC与全身可溶性免疫检查点的广泛变化有关,主要是共抑制分子的升高.
- TGF-β1可能在驱动BCC免疫抑制方面发挥重要作用,可能通过调节性T细胞激活.
- 这些免疫失调存在于新诊断的和复发的BCC疾病中.
相关概念视频
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


